LAG3 and cancer: As diabetes is known to be an independent risk factor for several types of cancer, and diabetic subjects have higher cancer-related mortality compared to subjects without diabetes [9–11], our results suggested that the reduced expression of LAG3 could hinder the effect of anti-LAG3 treatments in diabetic patients with advanced melanoma.